Mifamurtide sodium hydrate

Modify Date: 2024-01-28 18:03:25

Mifamurtide sodium hydrate structure	Common Name	Mifamurtide sodium hydrate
	CAS Number	838853-48-8	Molecular Weight	1277.496
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₅₉H₁₁₀N₆NaO₂₀P	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Mifamurtide sodium hydrate

Mifamurtide (sodium hydrate) (MTP-PE (sodium hydrate); L-MTP-PE (sodium hydrate); CGP 19835 (sodium hydrate)) is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research[1][2][3].

Name	Mifamurtide hydrate
Synonym	More Synonyms

Description	Mifamurtide (sodium hydrate) (MTP-PE (sodium hydrate); L-MTP-PE (sodium hydrate); CGP 19835 (sodium hydrate)) is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
References	[1]. Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89. [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5. [3]. Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

References

[1]. Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89.

[2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.

[3]. Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3.

Molecular Formula	C₅₉H₁₁₀N₆NaO₂₀P
Molecular Weight	1277.496
Exact Mass	1276.740967

Mifamurtide

Sodium (5S,10R,13S,16R)-16-{[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}-10-carbamoyl-5,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadec-1-yl (2R)-2,3-bis(palmitoyloxy)propyl phosphate hydrate (1:1:1)

Mifamurtide sodium hydrate

Use of Mifamurtide sodium hydrate

Names

Mifamurtide sodium hydrate Biological Activity

Chemical & Physical Properties

Synonyms